A Phase 2b Study of Zagociguat in Patients With MELAS

NCT06402123 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Interventions

DRUG: zagociguat 15mg
DRUG: zagociguat 30mg
DRUG: Placebo

Sponsor

Tisento Therapeutics